Figure 1 4 Evidence framework and phenotypic heterogeneity of GLP-1RA-associated taste-related changes In real-world obesity treatment, some patients receiving GLP-1RAs report changes in eating experience, such as food tastes different, food is no longer appealing, or the emergence of unpleasant taste sensations (10)
These SCFAs activate G-protein-coupled receptors on L-cells to trigger GLP-1 release
It is important to recognise that patients prescribed GLP-1 agonists often have underlying conditionssuch as type 2 diabetes, obesity, hypertension, and dyslipidaemiathat independently increase cardiovascular and thrombotic risk
Mehdi, S
International Journal of Obesity, 39 (3), 424-429
Adjusted odds ratios (aORs) for predefined outcomes were determined via multivariable logistic and linear regression analyses